Trial Profile
A Phase 1, Randomized, Multi-center, Double-blind, Sponsor Open, Placebo-controlled, Single And Multiple Dose-escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs PF-06835375 (Primary) ; PF-06835375 (Primary)
- Indications Rheumatoid arthritis; Systemic lupus erythematosus
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 03 Jun 2023 Results presented at the 24th Annual Congress of the European League Against Rheumatism
- 01 Mar 2022 Status changed from active, no longer recruiting to completed.
- 27 Jan 2022 Planned End Date changed from 30 Dec 2021 to 15 Feb 2022.